Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30. doi:10.3322/caac.21387. PMID:28055103
   PubMed Web of Science ®Google Scholar
• Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, et al. New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur Urol. 2011;60:279-90. doi:10.1016/j.eururo.2011.04.038. PMID:21592649
   PubMed Web of Science ®Google Scholar
• Maluf FC, Smaletz O, Herchenhorn D. Castration-resistant prostate cancer: Systemic therapy in 2012. Clinics (Sao Paulo, Brazil). 2012;67:389-94. doi:10.6061/clinics/2012(04)13. PMID:22522765
   PubMed Web of Science ®Google Scholar
• Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16:4583-94. doi:10.1158/1078-0432.CCR-10-0733. PMID:20702612
   PubMed Web of Science ®Google Scholar
• Chen G, Emens LA. Chemoimmunotherapy: Reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203-16. doi:10.1007/s00262-012-1388-0. PMID:23389507
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-35. doi:10.3322/caac.20132. PMID:22576456
   PubMed Web of Science ®Google Scholar
• Emens LA. Chemoimmunotherapy. Cancer J (Sudbury, Mass). 2010;16:295-303. doi:10.1097/PPO.0b013e3181eb5066. PMID:20693839
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Antonia S, Gabrilovich DI. Combined modality immunotherapy and chemotherapy: A new perspective. Cancer Immunol Immunother. 2008;57:1523-9. doi:10.1007/s00262-008-0531-4. PMID:18488219
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: Improving vaccines? Adv Drug Deliv Rev. 2006;58:975-90. doi:10.1016/j.addr.2006.04.002. PMID:17005292
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-52. doi:10.1038/32588. PMID:9521319
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265-77. doi:10.1038/nrc3258. PMID:22437871
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2012;1:1111-34. doi:10.4161/onci.21494. PMID:23170259
   PubMed Web of Science ®Google Scholar
• Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 2015;6:18192-205. doi:10.18632/oncotarget.4145. PMID:26078335
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22. doi:10.1056/NEJMoa1001294. PMID:20818862
   PubMed Web of Science ®Google Scholar
• Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. 2015;6:663. PMID:26834740
   PubMed Web of Science ®Google Scholar
• Adkins I, Fucikova J, Garg AD, Agostinis P, Spisek R. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 2014;3:e968434. doi:10.4161/21624011.2014.968434. PMID:25964865
   PubMed Web of Science ®Google Scholar
• Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron PF, Houska M, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135:1165-77. doi:10.1002/ijc.28766. PMID:24500981
   PubMed Web of Science ®Google Scholar
• Mikyskova R, Stepanek I, Indrova M, Bieblova J, Simova J, Truxova I, Moserová I, Fučíková J, Bartůňková J, Špíšek R, et al. Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. Int J Oncol. 2016;48:953-64. PMID:26718011
   PubMed Web of Science ®Google Scholar
• Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 1999;2:70-5. doi:10.1038/sj.pcan.4500296. PMID:12496841
   PubMed Web of Science ®Google Scholar
• Mikyskova R, Indrova M, Simova J, Jandlova T, Bieblova J, Jinoch P, Bubeník J, Vonka V. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int J Oncol. 2004;24:161-7. PMID:14654953
   PubMed Web of Science ®Google Scholar
• Indrova M, Mikyskova R, Jandlova T, Vonka V, Bubenik J, Bieblova J. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: Cytolytic activity of spleen cells from tumour regressors. Folia Biol (Praha). 2003;49:217-22. PMID:14748435
   PubMed Web of Science ®Google Scholar
• Bubenik J, Mikyskova R, Vonka V, Mendoza L, Simova J, Smahel M, Indrová M. Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine. 2003;21:891-6. doi:10.1016/S0264-410X(02)00537-6. PMID:12547599
   PubMed Web of Science ®Google Scholar
• Reinis M, Indrova M, Mendoza L, Mikyskova R, Bieblova J, Bubenik J, Símová J. HPV16-associated tumours: Therapy of surgical minimal residual disease with dendritic cell-based vaccines. Int J Oncol. 2004;25:1165-70. PMID:15375569
   PubMed Web of Science ®Google Scholar
• Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 1996;56:21-6. PMID:8548765
   PubMed Web of Science ®Google Scholar
• Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57:3325-30. PMID:9269988
   PubMed Web of Science ®Google Scholar
• Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92. doi:10.1016/S0022-1759(98)00204-X. PMID:10037236
   PubMed Web of Science ®Google Scholar
• Indrova M, Reinis M, Bubenik J, Jandlova T, Bieblova J, Vonka V, Velek J. Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha). 2004;50:184-93. PMID:15709713
   PubMed Web of Science ®Google Scholar
• Stepanek I, Indrova M, Bieblova J, Fucikova J, Spisek R, Bubenik J, Reinis M. Effects of 5-azacytidine and trichostatin A on dendritic cell maturation. J Biol Regul Homeost Agents. 2011;25:517-29. PMID:22217985
   PubMed Web of Science ®Google Scholar
• Yi AK, Krieg AM. CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. J Immunol. 1998;160:1240-5. PMID:9570540
   PubMed Web of Science ®Google Scholar
• Vlk V, Rossner P, Indrova M, Bubenik J, Sobota V. Interleukin-2 gene therapy of surgical minimal residual tumour disease. Int J Cancer. 1998;76:115-9. doi:10.1002/(SICI)1097-0215(19980330)76:1<115::AID-IJC18>3.0.CO;2-B. PMID:9533770
   PubMed Web of Science ®Google Scholar
• Bubenik J, Zeuthen J, Indrova M, Bubenikova D, Simova J. Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer. Int J Oncol. 1994;4:13-6. PMID:21566882
   PubMed Web of Science ®Google Scholar
• Mikyskova R, Indrova M, Pollakova V, Bieblova J, Simova J, Reinis M. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors. J Immunother. 2012;35:374-84. doi:10.1097/CJI.0b013e318255585a. PMID:22576342
   PubMed Web of Science ®Google Scholar
• Mikyskova R, Indrova M, Vlkova V, Bieblova J, Simova J, Parackova Z, Pajtasz-Piasecka E, Rossowska J, Reiniš M. DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment. J Leukoc Biol. 2014;95:743-53. doi:10.1189/jlb.0813435. PMID:24389335
   PubMed Web of Science ®Google Scholar
• Ricupito A, Grioni M, Calcinotto A, Hess Michelini R, Longhi R, Mondino A, Bellone M. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res. 2013;73:3545-54. doi:10.1158/0008-5472.CAN-12-2449. PMID:23539449
   PubMed Web of Science ®Google Scholar
• Chin AI, Miyahira AK, Covarrubias A, Teague J, Guo BC, Dempsey PW, Cheng G. Toll-like Receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010;70:2595-603. doi:10.1158/0008-5472.CAN-09-1162. PMID:20233880
   PubMed Web of Science ®Google Scholar
• Lion E, Smits ELJM, Berneman ZN, Van Tendeloo VFI. NK Cells: Key to success of DC-based cancer vaccines? Oncologist. 2012;17:1256-70. doi:10.1634/theoncologist.2011-0122. PMID:22907975
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fujii SI. DC therapy induces long-term NK reactivity to tumors via host DC. Eur J Immunol. 2009;39:457-68. doi:10.1002/eji.200838794. PMID:19180466
   PubMed Web of Science ®Google Scholar
• Bonaccorsi I, Pezzino G, Morandi B, Ferlazzo G. Novel perspectives on dendritic cell-based immunotherapy of cancer. Immunol Lett. 2013;155:6-10. doi:10.1016/j.imlet.2013.09.021. PMID:24076312
   PubMed Web of Science ®Google Scholar
• Mendoza L, Indrova M, Hajkova R, Reinis M, Smahel M, Vonka V, Bubeník J, Jandlová T. Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth. Folia Biol-Prague. 2000;46:91-7.
   PubMed Web of Science ®Google Scholar
• Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, Bubenik J. Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines. Int J Oncol. 2010;36:545-51. doi:10.3892/ijo_00000528. PMID:20126973
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098-104. doi:10.1158/1078-0432.CCR-07-4875. PMID:18483377
   PubMed Web of Science ®Google Scholar